7,648.25

+34.25

+0.45%

52,097.00

+179.00

+0.34%

28,770.75

+236.75

+0.83%

Russell 2000 Futures

2,836.60

+15.30

+0.54%

4.9290

-0.0600

-1.20%

19.42

+2.22

+12.91%

3,916.60

+17.70

+0.45%

78,055.67

+239.81

+0.31%

Crude Oil Dec 26

100.83

-3.29

-3.16%

US Private Equity

10,850.63

-82.20

-0.75%

KSE - Delayed Quote KRW

SK bioscience Co.,Ltd. (302440.KS)

33,500.00 +750.00 (+2.29%)

As of 2:36:09 PM GMT+9. Market Open.

SK bioscience Launches AI-Powered Initiative to Reduce Uncertainty in Vaccine-Development Decisions

PR Newswire 3mo ago

302440.KS
+2.29%
SK bioscience Secures First UNICEF Procurement Contract Improving Vaccine Access

PR Newswire 4mo ago

302440.KS
+2.29%
SK bioscience Board Approves Financing Plan Supported by Korea Growth Fund

PR Newswire 5mo ago

302440.KS
+2.29%
SAN.PA
SK bioscience and VECOL partner on Colombia vaccine manufacturing initiative

Pharmaceutical Technology 5mo ago

302440.KS
+2.29%
SK bioscience Signs Vaccine Technology Transfer Agreement with Colombia's VECOL to Advance Local Vaccine Manufacturing in Latin America

PR Newswire 5mo ago

302440.KS
+2.29%
SK bioscience Advances Development of Next-Generation Infectious Disease Prevention Platform with Global Phase 1b CTA Submission for RSV Preventive Antibody Candidate

PR Newswire 2mo ago

302440.KS
+2.29%
SKBS
Novavax Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

PR Newswire 8mo ago

NVAX

SAN.PA

PFE

Mobilize your Website

View Site in Mobile | Classic

Share by: